Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05637333
Other study ID # CRC/2022/004
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date December 15, 2022
Est. completion date May 15, 2023

Study information

Verified date March 2023
Source London North West Healthcare NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Currently, Sonazoid is mainly used for imaging liver lesions by assessing perfusion characteristics. However, the ultrasound technology is the same as for cardiac imaging and the stability of the microbubbles will potentially aid the detection of myocardial perfusion defects. This study will look at the feasibility of using sonozoid in this way.


Description:

Ultrasound contrast agents are gas-filled microbubbles that enhance the visualisation of cardiac structures, function and blood flow. Myocardial contrast echocardiography enables us to visualise myocardial perfusion and provides incremental information for diagnosis of coronary artery disease (CAD) and prognosis beyond wall motion assessment . Using ultrasound at low acoustic power (low/intermediate MI) causes the microbubbles to oscillate resulting in giving off non-linear signals which are different from tissues which gives off linear signals. The first contrast agents were used in 1968. Since then the technology has been refined and now the microbubbles are more stable and consist of an inert gas encapsulated in a lipid or albumin shell. These microbubbles remain intact in the systemic circulation because of their small size can transit through the pulmonary circulation. The indication for myocardial perfusion imaging is when vasodilator stress like Dipyridamole is performed. Vasodilators do not readily induce wall motion abnormalities but cause perfusion defects to occur which allows detection of CAD. Myocardial perfusion imaging is also indicated during treadmill or dobutamine stress when suspicion of CAD is high as it is more sensitive than wall motion for the detection of CAD. Myocardial perfusion imaging looks at a uniformity of contrast appearance in the myocardium, following a continuous microbubble infusion. If there is decreased perfusion, the appearance of contrast will be delayed and the opacification will not be uniform. The advantage of Sonazoid over the other frequently used contrast agents (Sonovue, Luminity, Optison) is that the microbubbles are more robust, allowing for a higher MI setting to be used during scanning. The higher MI setting enhances higher intensity bubble signal with improved spatial and temporal resolution which improves image quality and diagnostic accuracy. This study is not looking for diagnosis in patients, which will be done according to standard of care. It is to evaluate whether it is possible to assess myocardial perfusion using the contrast agent Sonazoid.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 15, 2023
Est. primary completion date April 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Positive and normal Clinical SE - Able to provide informed consent Exclusion Criteria: - Unable / unwilling to give informed consent - Allergy to Perfluorobutane - Egg allergy - Patients with right to left arteriovenous cardiac or pulmonary shunt - Unstable heart disease - Serious pulmonary disease - Pregnancy or lactation Women of child bearing potential (defined as not chemically or surgically sterilised or post menopausal)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Contrast Stress Echocardiography
Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.

Locations

Country Name City State
United Kingdom London North West University Healthcare NHS Trust Harrow Middx

Sponsors (1)

Lead Sponsor Collaborator
London North West Healthcare NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To demonstrate if sonazoid gives adequate opacification of the myocardium at low mechanical index using stress echocardiography Contrast Stress echocardiography (SE) using sonazoid will be used to predict if patients with very low probability of CAD have flow-limiting coronary stenosis>70% in any major coronary artery branches in patients with previous significant (>2 contiguous segments) inducible ischemia on stress echocardiography (SE). 1 day
Primary To demonstrate if sonazoid gives adequate opacification of the myocardium at intermediate mechanical index using stress echocardiography Contrast Stress echocardiography (SE) using sonazoid will be used to predict if patients with very low probability of CAD have flow-limiting coronary stenosis>70% in any major coronary artery branches in patients with previous significant (>2 contiguous segments) inducible ischemia on stress echocardiography (SE). 1 day
Secondary Myocardial blood flow reserve assessment for prediction of flow-limiting CAD Myocardial blood flow will be measured during the scan 1 day
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Completed NCT01434043 - Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging